Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir.
Susceptibilities to brovavir [1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)-uracil] and acyclovir of clinical isolates of varicella-zoster virus obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method. All 101 isolates were significantly susceptible to brovavir; 50% effective dose of brovavir for these isolates ranged between 0.6-4.0 ng/ml (average: 1.29 ng/ml). Brovavir was about 3,000 times more potent than acyclovir against these isolates. No marked change in the susceptibility of isolates from these patients during treatment with brovavir was observed.
Machida
H
H
Biology Laboratory, R & D Division, Yamasa Shoyu Co., Ltd., Chiba.
Nishitani
M
M
D000212:Acyclovir / Q000494:pharmacology; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002460:Cell Line; D006562:Herpes Zoster / Q000188:drug therapy / Q000382:microbiology; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D014529:Uridine / Q000031:analogs & derivatives*
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C031368:sorivudine; D014529:Uridine; D000212:Acyclovir